Rimonabant Acomplia Online InformationRimonabant Acomplia Online InformationInformation about what and why Rimonanabant Acomplia is the wonder of diet pills medicine Articles
How to Read a Nutrition Label part 3?
2007-08-10 02:46:00 The Important Term That’s Not on Label s A desire to lose weight may be the main reason you pay attention to what you eat. But eating to promote good health should be a consideration as well. Labels can help. In 1993, the FDA required manufacturers to list saturated fat and cholesterol on nutrition labels. Now the ... More About: Nutrition , Read , Part , Part 3
How to Read a Food Label continued?
2007-08-10 02:44:00 The Nutrition Facts Label Serving Size Start your label reading adventure by looking at the “serving size” printed right under “nutrition facts.” Portion control is an important part of weight management, but don’t expect food manufacturers to make it easy for you. Pop-Tarts, for instance, come two to a package. The label says one serving is 200 ... More About: Food , Read , Abel , Conti
How to Read a Food Label
2007-08-10 02:42:00 Remember being a kid and tearing open the cereal box to get the special decoder ring? Today’s cereals should come with a ring you can use to crack the code of their nutrition labels. For those who understand its secrets, the nutrition label holds valuable information for winning the war on fat. Since there is ... More About: Food , Read , Label , Abel
Order Acomplia Online
2007-08-10 02:29:00 Something to remember: Rimonabant’s benefits are by helping to reduce appetite, and thus help those who use the drug lose weight. There is also hope that Acomplia will help the health of patients in other ways. There is also evidence that it helps with lipid levels (such as cholesterol) in the blood and might help with ... More About: Online , Order
Vexing Month for Sanofi Over Rimonabant Likely to Hit Peak in Coming Week
2007-08-10 02:25:00 What has been vexing month for Sanofi -Aventis and its highly anticipated diet pill rimonabant (Acomplia / Zimulti) — with the introduction of competing versions of rimonabant in India before the drug Sanofi originated has been approved for sale — seems likely to reach a peak in the week ahead. On Tuesday, June 12th, the U.S. FDA ... More About: Week , Peak , Rimonabant , Ming
Delay in Approval of Diet Pill Rimonabant in U.S. Tied to ?Psychiatric Adve
2007-08-10 02:24:00 June 2007 The refusal of the FDA thus far to approve sale of diet drug rimonabant (Acomplia / Zimulti) in the United States is the result of concern over “increased frequencies of psychiatric adverse effects” including suicide and seizures, the agency’s staff disclosed on June 11th. The confirmation of long-rumored FDA worries over the neuropsychiatric side-effects of ... More About: Diet , Rimonabant , Chia , Mona
European Regulators Decide Diet Drug Rimonabant Should Remain on the Market
2007-08-08 15:20:00 While diet drug rimonabant may double your risk of depression, its benefits “continue to outweigh its risks” for overweight and obese individuals who are not taking antidepressants, European drug regulators concluded on July 19th. But in deciding to let Acomplia remain on the market in Europe, the regulators expressed concern that “too many patients are taking ... More About: Diet , Market , Drug , Rimonabant
Mythology of Acomplia Plays to Magic Pill Approach to Health part 3
2007-08-08 15:13:00 Now certainly, genes can be a factor. There are some people who are born with greater ability to store food as body fat. There are other people born with stronger hearts. Some people didn’t get good nutrition when they were infants, because their pregnant mothers didn?t know about good nutrition and didn’t feed them well, ... More About: Mythology , Health , Magic , Part , Plays
Mythology of Acomplia Plays to Magic Pill Approach to Health part 2
2007-08-08 15:12:00 The seduction of Acomplia is that it takes over our responsibilities. It allows us to shift control of our lives from our own conscious intentions to a prescription drug handed out to us by doctors. It is in this very mythology that the danger to Americans hides. Not in the drug itself — it is ... More About: Mythology , Health , Magic , Part , Plays
Mythology of Acomplia Plays to Magic Pill Approach to Health
2007-08-08 15:11:00 Mike Adams, a holistic nutritionist who has authored a number of books on nutrition, wellness, food toxicology and the causes of disease and health, has written the following commentary on the weight-loss drug Acomplia . The views are his own, and are reported because of the widespread interest in this subject. A new weight loss drug, ... More About: Mythology , Health , Magic , Plays
Decisions Drawing Near on Approval of Sale of Acomplia
2007-08-08 15:09:00 January 2006 The moment of truth for the new diet drug Acomplia (rimonabant), currently awaiting decisions on regulatory approval both in the United States and Europe, would appear to be drawing near. Sanofi-Aventis, which developed the drug, submitted Phase III clinical trial results to both the U.S. Food and Drug Administration and European regulators early last summer, ... More About: Drawing , Sale , Draw , Decisions
Waiting for More Rimonabant Trial Results
2007-08-08 15:08:00 January 2005 When two year results of the RIO-North America (Rimonabant In Obesity) trial were presented at the American Heart Association (AHA) scientific meeting in New Orleans in November, researchers said additional results from studies underway could be expected by the end of the year. But seven weeks have passed with no news on when additional data ... More About: Results , Trial , Rial , Waiting
Diet Drug Rimonabant May Reduce Obesity-Related Liver Damage
2007-08-08 14:55:00 A new study on rimonabant (Acomplia / Zimulti) has identified yet one more possible health benefit for this controversial diet drug: it appears to reduce obesity-related liver damage that can lead to cirhossis of the liver. A team of researchers led by Mohammed Bensaid of Sanofi-Aventis, the company that has developed rimonabant, reported on these latest ... More About: Diet , Obesity , Reduce , Drug , Related
Sanofi Holds Little Hope for Early U.S. Sale of Acomplia / Zimulti (Rimonab
2007-08-05 19:13:00 Diet drug Acomplia / Zimulti (rimonabant) has now been taken by more than 200,000 obese and overweight patients in Europe and a handful of other countries, but Sanofi -Aventis offered no encouragement on Aug. 1 to those hoping to see it approved for early sale in the United States. Executive Vice President Hanspeter Spek, talking to financial ... More About: Sale , Hope , Early , Hold
Top Marketeer Returns to Merck to Promote Diet Drug Acomplia Competitor
2007-08-05 19:11:00 In the latest sign that things are going will with Merck ’s development of a competitor to diet drug Acomplia (rimonabant), the pharmaceutical giant is bringing back Len Tacconi to serve as global brand leader for its weight-loss drug taranabant. Tacconi, who left Merck less than a year ago to become president of Discovery Health, spent a ... More About: Diet , Promote , Drug , Turn
Diet Drug Acomplia Sales Dwarfed by Initial Sales of Diet Pill alli
2007-08-05 19:10:00 Just how badly sales of diet drug Acomplia (rimonabant) have been set back by Sanofi’s inability to bring it to the U.S. market was dramatically illustrated July 25th when GlaxoSmithKline revealed initial launch results for over-the-counter diet pill alli (low-dose Xenical). Sales of non-prescription alli totaled a surprising $156 million in the weeks after its U.S. ... More About: Diet , Alli , Drug
Diet Drug Acomplia (Rimonabant) Further Delayed by U.S. FDA
2007-08-02 01:38:00 Diet drug Acomplia (rimonabant), stalled at the U.S. Food and Drug Administration for more than a year, now will not be acted on at least until the end of July, Sanofi-Aventis announced on February 12th. The French pharmaceutical company said that in an effort to approve chances that Acomplia will be approved for sale in the ... More About: Diet , Rimonabant , Mona
Diet Drug Alli (Low-Dose Xenical) approved by FDA for Nonprescription Sale
2007-08-02 01:36:00 The U.S. Food and Drug Administration, after months of unexplained delay, on Feb. 7th approved Alli — a half-strength version of prescription diet drug Xenical (orlistat) — as the first FDA-approved diet pill to be sold over-the-counter in the United States. The FDA action leaves the Sanofi-Aventis prescription diet pill Acomplia (rimonabant) as the only weight-loss ... More About: Diet , Sale
Diet Drug Acomplia (Rimonabant) Gets French OK
2007-08-02 01:35:00 Diet drug Acomplia (rimonabant) on Feb. 6th received a “‘favorable recommendation” for reimbursement by French health insurance companies and state social security plans for use limited to obese patients with type 2 diabetes insufficiently controlled by customary diabetes drugs. The independent Transparency Committee, however, apparently did not recommend reimbursement for patients who are overweight or obese ... More About: Diet , Drug , Rimonabant
Sanofi Says Acomplia Could Be on Market by June 30th if FDA Gives OK in Feb
2007-08-02 01:34:00 February 2006 Sanofi -Aventis, developer of the novel weight-loss drug Acomplia (rimonabant), continues to hint that it expects the U.S. FDA to approve the drug in the next few weeks — enabling doctors to begin prescribing it before the end of June . The Philadelphia Inquirer reported on Feb. 4th that If Acomplia gets marketing approval from the FDA ... More About: Market
Most Significant ?Wait Loss? for Diet Drug Acomplia Is Loss of Sanofi?s Hug
2007-08-02 01:32:00 As month after month passes with no sign of imminent FDA action on diet drug rimonabant (Acomplia / Zimulti), the most significant “wait loss” taking place is loss of the hugh lead Sanofi -Aventis once had in developing a novel approach to weight-loss based on blocking the CB-1 receptors in the brain. A year ago, the French ... More About: Diet , Loss , Drug
Marijuana ?munchies? lead to possible diet drug
2007-08-02 01:31:00 The beginning of acomplia rimonabant Mari juana users call them “the munchies,” those intense food cravings sparked by inhaling the illicit weed’s smoke. Normally blamed for weight gain, these urges to wolf down everything in sight now have led to the development of a drug that may help millions slim down. Called Rimonabant, the experimental pill appears to ... More About: Diet , Drug , Lead
New Acomplia Trial Announced, But Enrollment Said Almost Completed
2007-08-02 01:29:00 February 2006 A new phase III clinical trial designed to explore whether the weight-loss drug Acomplia (rimonabant) can slow atherosclerosis, the fatty build-up in arteries that creates heart attack risk, was announced February 1 by researchers at the University of Rochester Medical Center. Results of previous studies have shown that Acomplia reduces triglycerides and increases HDL ?good? ... More About: Trial , Rial , Complete , Said
Sanofi to Present More Acomplia Data at April 11th Meeting
2007-08-02 01:28:00 February 2005 Sanofi -Aventis, developer of the highly publicized anti-obesity drug Acomplia , will present new data on the drug’s role in reducing metabolic cardiovascular disease risk factors at a scientific meeting in San Diego April 11th and 12th. Dr. Pierre Rosenzweig, a Vice President of Sanofi-Aventis, will make the presentation at the Annual Metabolic Diseases Drug Discovery ... More About: Data , Present
UK Company Plans Trial of Diet Drug With Same Target as Acomplia (Rimonaban
2007-08-02 01:27:00 GW Pharmaceuticals, a U.K. company with an announced goal of being the global leader in prescription cannabinoid medicine, said on Jan. 30 it hopes to soon start a Phase I clinical trial of an experimental diet drug derived from cannabis. The company said researchers had found cannabis not only contains an active ingredient called tetrahydrocannabinol (THC) ... More About: Diet , Company , Trial , Plans , Target
Sanofi Expresses Confidence Acomplia Will Be Available in U.S. in a Few Mon
2007-08-02 01:26:00 January 2006 Sanofi -Aventis, developer of Acomplia (rimonabant), told financial analysts on Jan. 30th it is “very, very confident” it will be permitted to begin selling the highly anticipated weight-loss drug in the United States in the spring of this year. “We can only report that our collaboration with the FDA is excellent. We have developed the product ... More About: Confidence , Express , Available
Two FDA Advisory Committees Back Over-the-Counter Sale of Low-Dose Xenical
2007-07-28 17:54:00 Two U.S. Food and Drug Administration (FDA) advisory committees voted on January 23rd to recommend that the regulatory agency approve GlaxoSmithKline’s petition to sell a half-dose version of the diet drug Xenical (orlistat) without a prescription. The FDA advisory committees, following an all-day meeting at which they heard arguments both for and against approving the proposed ... More About: Sale , Back , Counter , Committee
Sanofi to Improve ?Communication,? But Not About FDA and Diet Drug Acomplia
2007-07-28 17:52:00 The new chief executive of Sanofi Aventis, Gérard Le Fur, says the company needs to improve its ‘communication,’ but not by disclosing why diet drug Acomplia (rimonabant) has been stalled for more than a year at the U.S. Food and Drug Administration. Le Fur, the former research chief at Sanofi who took over this month as ... More About: Communication , Diet , Improve
FDA Raises Warning Flags on Over-the-Counter Sale of Low-Dose Xenical
2007-07-28 17:50:00 The U.S. Food and Drug Administration (FDA) staff has raised a variety of warning flags in advance of an advisory committee meeting set for Jan. 23rd to consider GlaxoSmithKline’s petition to sell a half-dose version of the diet drug Xenical (orlistat) without a prescription. The FDA staff, in documents released on Jan. 19th, questioned whether the ... More About: Sale , Warning , Counter , Dose
Article Urges FDA to Limit Acomplia to ?Those Who Need the Drug to Survive?
More articles from this author:2007-07-28 17:48:00 A Virginia Tech student newspaper has gotten quite a bit of attention in the past two days with an article on Acomplia suggesting that while a pill that combats obesity and potentially decreases the risk of heart complications sounds like a great idea, it “could end up creating more problems than it solves.” In the article, ... More About: Article , Survive , Drug , Vive 1, 2, 3, 4, 5 |
 |
|
 |
